论文部分内容阅读
目的探讨丝裂霉素C和羟基喜树碱灌注治疗膀胱肿瘤切除患者的临床效益,为治疗膀胱肿瘤积累经验。方法选取2007年4月至2013年2月收治的膀胱肿瘤切除患者48例,采用随机数字表法分为观察组和对照组,每组24例。对照组患者采取丝裂霉素C灌注治疗,观察组患者采取羟基喜树碱灌注治疗,比较两组患者2年内复发率、不良反应发生率以及成本和效果情况。结果观察组患者术后2年复发率为12.5%,对照组为25.0%,差异有统计学意义(P<0.05)。观察组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05)。观察组成本效果比值高于对照组,差异无统计学意义(P>0.05)。结论膀胱癌患者术后采取羟基喜树碱灌注治疗方案的成本和效果优于丝裂霉素C灌注治疗方案。羟基喜树碱灌注治疗方案临床效果较佳,值得进一步推广。
Objective To investigate the clinical effects of mitomycin C and hydroxycamptothecin in patients with bladder tumor resection and to accumulate experience in the treatment of bladder cancer. Methods Forty-eight patients with bladder tumor resected from April 2007 to February 2013 were randomly divided into observation group and control group with 24 cases in each group. The patients in the control group were treated with mitomycin C infusion. The patients in the observation group were treated with hydroxycamptothecin infusion. The recurrence rate, incidence of adverse reactions, costs and effects within two years in both groups were compared. Results The recurrence rate of 2-year postoperative patients was 12.5% in the observation group and 25.0% in the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in observation group was lower than that in control group, the difference was statistically significant (P <0.05). The ratio of the cost of the observation group was higher than that of the control group, with no significant difference (P> 0.05). Conclusion The cost and effect of HCPT in patients with bladder cancer after operation is superior to mitomycin C infusion therapy. Hydroxycamptothecin perfusion therapy clinical effect is better, it is worth further promotion.